Drug Discovery
Ulefnersen slows ALS decline in pivotal FUS gene trial
A Phase 3 trial finds ulefnersen, an RNA-targeted therapy from Otsuka and Ionis Pharmaceuticals, significantly slows disease progression in patients with FUS-associated ALS.
